Navigation Links
Seahorse Bioscience Announces AACR Travel Award Recipients
Date:4/4/2013

BILLERICA, Mass., April 4, 2013 /PRNewswire/ -- Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism announces travel award recipients who will present data generated using XF technology at the American Association of Cancer Research (AACR) Annual Meeting, in Washington, DC, April 6-10, 2013.

  • Kate M. Bailey , Ph.D., candidate in the lab of Robert J. Gillies , Ph.D., at the H. Lee Moffitt Cancer Center in Tampa, FL. Poster Title: Manipulating the tumor microenvironment for therapeutic benefit:  identifying mechanisms of buffer resistance.

 

  • Ekaterina S. Moroz , MD., visiting investigator at the Memorial Sloan Kettering Cancer Center, in New York, NY. Poster title: Metabolic characterization of prostate cancer cell lines. 

 

  • Divya Pathania , Ph.D., postdoctoral fellow at the University of Southern California, in Los Angeles, CA. Poster title: Design and discovery of novel small molecule redox modulators as therapies for pancreatic cancer.

 

  • Praveen K. Vayalil , Ph.D., research associate in the lab of Aimee Landar Ph.D., at the Center for Free Radical Biology, Department of Pathology, at the University of Alabama at Birmingham, Birmingham, AL. Poster title: Mitochondrial bioenergetics of metastatic breast cancer cells in response to decreasing oxygen tension.

Seahorse travel awards are offered to graduate students, post-doctoral researchers, and young investigators who present a talk or poster citing data generated on the XF platform at scientific meetings and conferences. Through this program, Seahorse seeks to increase the body of knowledge that is enabling new discoveries about the role of cell metabolism in pathophysiology, and in particular cancer.

"One focus of our lab's research is to therapeutically target the acidic microenvironment of solid tumors using buffers, which we have shown reduces metastasis in many tumor types. Seahorse XF technology allowed us to classify buffer sensitive and resistant tumor types, based on their metabolic phenotypes. A greater understanding of tumor metabolism has proven essential to effectively target the tumor microenvironment in pre-clinical and clinical settings," stated Kate Bailey , Ph.D., from the H. Lee Moffitt Cancer Center in Tampa, FL.   

The Seahorse XFe Extracellular Flux Analyzer and stress test kits standardize the measurement of mitochondrial function and cancer metabolism, in real-time, in a microplate. In minutes, the XFe Analyzer measures the oxygen consumption rate (OCR) -- a measure of mitochondrial respiration -- and the extracellular acidification rate (ECAR) -- a measure of glycolysis  -- to providing the most physiologically relevant in vitro measurement of cancer metabolism available today.

"The composition and characteristics of the tumor microenvironment vary widely and are important in determining the anti-tumor immune response. In our lab we assess how an abnormal tumor microenvironment affects T-cell activation and tumor targeting function in a prostate cancer model. We used the XF Analyzer to characterize cellular bioenergetics in prostate cancer cells. A greater understanding of how the metabolic processes work, may enable us to modify components of the tumor microenvironment to increase the efficacy of T-cell adoptive therapy," stated Ekaterina Moroz , M.D., from the Memorial Sloan Kettering Cancer Center, in New York, NY.

Studies utilizing XF technology are revealing the metabolic dependencies of cancer cells on glucose or other substrates, such as glutamine and fatty acids. With this knowledge scientists are now able to determine cancer cell substrate preferences, and establish potential pathways to target for intervention.

"The XF Analyzer is unique technology that has provided us with an incredible platform for measuring the changes in cellular oxygen consumption, and extracellular acidification, in real-time. The XF24 Analyzer has helped us to identify small, novel molecules that are able to exert anti-cancer effects by modulating bioenergetics and redox state," said  Divya Pathania , Ph.D., from the University of Southern California, in Los Angeles, CA.

"We've been investigating the bioenergetic response during adaptation to low oxygen tension by highly metastatic breast cancer cells. The XF Analyzer was the technology that enabled us to measure these responses, under hypoxic conditions, in real-time. This knowledge is now leading us to the discovery of a novel biphasic bioenergetic behavior by cancer cells, which may be useful as a target for cancer therapy," stated Praveen Vayalil , Ph.D., from the University of Alabama at Birmingham, Birmingham, AL.    

About Seahorse Bioscience

Seahorse Bioscience XFe Analyzers and stress test kits are the industry standard in cell metabolism measurements. Scientists worldwide are advancing their research in understanding the role of bioenergetics in Neurodegeneration, Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Obesity, Diabetes, Metabolic Disorders, Screening, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China.  Learn more about Seahorse Bioscience at www.seahorsebio.com.

About the H. Lee Moffitt Cancer Center

Moffitt Cancer Center in Tampa, Fla., is solely focused on the prevention and the cure of cancer. Moffitt, one of the world's most sophisticated cancer centers of excellence, employs fellowship-trained physicians and medical researchers who are among the best in their respective fields.

About the Memorial Sloan Kettering Cancer Center

Memorial Sloan–Kettering Cancer Center (MSKCC) is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, in Manhattan New York City. MSKCC has long been a leader in cancer surgery, chemotherapy, and radiotherapy and is the world's largest and oldest dedicated cancer hospital. It was the first to develop services specifically dedicated to the psychiatric aspects of cancer, to the relief of cancer pain, and to genetic counseling. 

About the University of Southern California

The University of Southern California (USC) is a private, not-for-profit, nonsectarian, research university founded in 1880 with its main campus in Los Angeles, California. As California's oldest private research university, USC has historically educated a large number of the region's business leaders and professionals. In recent decades, the university has also leveraged its location in Los Angeles to establish relationships with research institutions throughout Asia and the Pacific Rim. Reflecting the status of Los Angeles as a global city, USC has the largest number of international students of any university in the United States

About the University of Alabama at Birmingham

The University of Alabama at Birmingham (UAB) is a public university in Birmingham in the U.S. state of Alabama. Developing from an extension center established in 1936, the institution became an autonomous institution in 1969 and is today one of three institutions in the University of Alabama System. UAB offers over 140 programs of study in 12 academic divisions leading to bachelor's, master's, doctoral, and professional degrees in the social and behavioral sciences, the liberal arts, business, education, engineering, and health-related fields such as medicine, dentistry, optometry, nursing, and public health. The school is highly renowned for its medical research and natural sciences programs.

Press Contact:
Naomi Goumillout
Marketing Communications Manager
Seahorse Bioscience
ngoumillout@seahorsebio.com
1-978-671-1619


'/>"/>
SOURCE Seahorse Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
2. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
3. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
4. Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
5. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
6. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
7. Northstar Biosciences Launches All Natural Skincare Solutions
8. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
9. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
10. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
11. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):